In conclusion, PLGA‐PEG (si‐HECTD2#3) NPs effectively target HECTD2 and overcome lenvatinib resistance in vivo, supporting their potential for clinical application in HCC treatment. This evidence concerns the gene HECTD2 and hepatocellular carcinoma.